An interventional study of Manual needle localization and Real-time non-invasive localization in Lung Cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 8 that started in 2025, is one of 12 with no phase, and was the 22nd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 40–74 · Healthy volunteers
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 40–74 · Healthy volunteers
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 110 across the 18 interventional studies, 550 across the 8 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
7 of the studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150416The First Affiliated Hospital of Guangzhou Medical UniversityNebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study | 2026-12-01 |
| NCT06778512The First Affiliated Hospital of Guangzhou Medical UniversityLcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | 2026-12-01 |
| NCT06422637The First Affiliated Hospital of Guangzhou Medical UniversityA Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy | 2026-12-01 |
| NCT06843707The First Affiliated Hospital of Guangzhou Medical UniversityEstablishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. | 2026-12-31 |
| NCT07303881The First Affiliated Hospital of Guangzhou Medical UniversityGolidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares real-time non-invasive localization and manual CT-guided needle localization for multiple lung nodules under 20 mm. It primarily aims to evaluate the successful resection rate of pulmonary nodules.
This is a prospective, single-center, non-inferiority clinical study designed to evaluate the effectiveness of a real-time non-invasive localization. The study will be conducted between December 2025 to July 2026, involving 120 patients with multiple lung nodules smaller than 20 mm in diameter. Participants will be randomly assigned to receive either CT-guided manual needle localization or real-time non-invasive localization. The primary outcome measure will be the successful resection rate of pulmonary nodules. Secondary outcome measures will include resection margins, changes in operative approach, intraoperative blood loss, operative time, postoperative hospitalization days, the placement of chest tubes, the duration of chest tube placement, and postoperative complications.
The criteria were revised on the registry on Oct 22, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Real-time non-invasive localization of multiple pulmonary nodules
Procedure: Real-time non-invasive localization
Manual CT-guided percutaneous needle localization of multiple pulmonary nodules
Procedure: Manual needle localization
Manual needle localization involves the traditional technique of percutaneous localization of pulmonary nodules under CT guidance. The procedure is performed by the physician manually guiding the needle based on real-time CT imaging. The physician adjusts the needle position based on visual cues from the CT scan, which may require multiple attempts for accurate localization. After confirming the needle tip's proximity to the target nodule, indocyanine green (ICG) was injected during deep inspiration to mark the nodule for intraoperative fluorescence imaging. The thoracic surgeon completed resection of the pulmonary nodule based on the area delineated by ICG.
The patient underwent a CT scan prior to surgery. The acquired CT image data was saved in DICOM format and subsequently imported into software for three-dimensional reconstruction of the lung lobes, blood vessels, and bronchi. During the procedure, an assistant created a three-dimensional lung model on a separate monitor, aligning it roughly with the orientation of the deflated lung observed via thoracoscopy. The thoracic surgeon then completed resection of the pulmonary nodule guided by the surgeon's three-dimensional lung model.
The successful resection of all planned target nodules per patient
The primary outcome of this study was the successful resection of all planned target nodules per patient. A lesion was considered successfully resected if the surgical margin was equal to or greater than either the lesion diameter or 2 cm. Generally, after intraoperative resection of the lesion, the margin length was verified by direct measurement on the resected deflated lung specimen. If macroscopic measurement of the surgical margin was challenging, the distance from the nodule to the marker was assessed using intraoperative frozen section analysis. Additionally, any change in surgical approach resulting from unsuccessful nodule localization was considered a failure of lesion resection, regardless of margin size.
Time frame: Day of surgery.
Resection margins
Distance from the nodule to the resection margin
Time frame: Day of surgery.
Changes in operative approach
During surgery, the planned approach must be changed when the target nodule cannot be completely resected due to various reasons.
Time frame: Day of surgery.
Intraoperative blood loss
Hemorrhage during surgery.
Time frame: Day of surgery.
Operative time
Total duration of the thoracic surgical procedure, measured in minutes from skin incision to completion of skin closure for the index operation.
Time frame: Day of surgery.
Postoperative hospitalization days
The postoperative hospitalization duration refers to the total number of days the patient remains in the hospital from the completion of surgery until discharge.
Time frame: Perioperative.
The placement of chest tubes
Determine whether a chest tube needs to be placed based on the patient's condition during surgery.
Time frame: Day of surgery.
The duration of chest tube placement
The chest tube placement duration refers to the number of days from the placement of the chest tube after surgery until its removal.
Time frame: Perioperative.
Postoperative complications
Postoperative complications refer to any adverse events or symptoms that occur after surgery.
Time frame: Perioperative.
Ran from Dec 2025 to primary completion in Jul 2026, 7 months.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 7 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Jul 2024 → Dec 2025, primary completion May 2025 → Jul 2026 and completion Jul 2025 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Guangzhou Medical University →